A lifestyle disease prevention business based on measuring and managing vascular information

「In September 2026, as the first phase of the commercial rollout of the Cyvis series, we launched a Holter ECG testing support service for medical institutions using Cyvis M100.」

「In September 2026, as the first phase of the commercial rollout of the Cyvis series, we launched a Holter ECG testing support service for medical institutions using Cyvis M100.」

「The "Small Holter Electrocardiograph Medical Vital Sensor Cyvis M100," which forms part of this series, obtained medical device certification in November 2024. In addition to cardiac activity data, Cyvis can measure body-surface temperature, acceleration and other parameters, and the company is conducting operational studies involving not only medical institutions but also residents of welfare facilities, workers and others.」

「The company is developing the Cyvis series of ultra-compact vital sensors, which are designed to manage the risks of arrhythmia and atrial fibrillation and prevent myocardial infarction and cerebral infarction by routinely collecting, analyzing and processing with AI various types of healthcare data, including cardiac activity, brain activity, body temperature, SpO2 and activity levels. Cyvis also offers an optional function for measuring breathing during sleep, enabling convenient, highly accurate screening for the risk of SAS (sleep apnea syndrome). In August 2021, C2, which develops and operates the healthcare app Jukusui Alarm for visualizing sleep, became a consolidated subsidiary, and the group has continued to strengthen its healthcare business. Cyvis-2, the next model in the Cyvis series, was submitted for medical device certification in April 2023.」

「The next model in the Cyvis series, Cyvis-2, was submitted for medical-device certification in April 2023.」

「The photoacoustic imaging device Acoustic X uses an LED light-source system covered by the company's patents and enables real-time, high-resolution 3D imaging of peripheral blood vessels and blood without contrast agents and noninvasively. Research and development are being conducted under AMED's Medical-Engineering Collaboration Innovation Promotion Project (Development and Commercialization Program), while the company is pursuing medical-device status for the device as a next-generation medical imaging diagnostic system.」

「The first model in the Cyvis series, Cyvis-1, was registered as a medical device in April 2022, and trial provision to users began in May of the same year. Photoacoustic imaging for real-time analysis of microvascular information was selected for the Medical Engineering and Healthcare Innovation Program (Development and Commercialisation Project) of the Japan Agency for Medical Research and Development (AMED), and research and development is under way toward commercialising an imaging diagnostic device using a new imaging modality.」

「In August 2021, we acquired C2, which develops and operates the healthcare app Jukusei Alarm, which visualises sleep, and are strengthening the healthcare business as a group.」

「For the compact vital sensor Cyvis, intended to prevent and detect diseases such as myocardial infarction and cerebral infarction at an early stage, research and development has been completed and product commercialisation is under way. Photoacoustic imaging for real-time analysis of microvascular information was selected for the AMED Medical Engineering and Healthcare Innovation Program (Development and Commercialisation Project) of the Japan Agency for Medical Research and Development (AMED), and research and development is under way toward commercialising an imaging diagnostic device using a new imaging modality.」

「For compact vital sensors intended to prevent and detect disease at an early stage, we are adding new functions to improve the usability of the palm-sized arteriosclerosis monitor designed to detect arteriosclerosis and arrhythmia at an early stage. We are also advancing research and development into compact sensing devices for various vital signs, including electrocardiograms, and photoacoustic imaging for real-time analysis of microvascular information.」

「For compact vital sensors intended to prevent and detect disease at an early stage, we are adding new functions to improve the usability of the palm-sized arteriosclerosis monitor designed to detect arteriosclerosis and arrhythmia at an early stage. We are also advancing research and development into compact sensing devices for various vital signs, including electrocardiograms, and photoacoustic imaging for real-time analysis of microvascular information.」

「The palm-sized compact vital sensor, the electrocardiogram and pulse-wave testing device VS-AS01, intended to detect arteriosclerosis and arrhythmia at an early stage, is being prepared for external applications and other measures to improve usability.」

「The palm-sized compact vital sensor, the electrocardiogram and pulse-wave testing device VS-AS01, intended to detect arteriosclerosis and arrhythmia at an early stage, received marketing approval as a medical device from the Ministry of Health, Labour and Welfare in December 2018. Vascular elasticity testing using the product became eligible for coverage under public health insurance in January 2019. Preparations are currently under way, including external applications to improve usability ahead of general sales.」

「Our group is working to prevent and diagnose cardiovascular diseases such as myocardial infarction and stroke. It developed the palm-sized vital sensor VS-AS01, a compact device using an LED light source to detect arteriosclerosis and arrhythmia, the principal causes of these diseases, at an early stage, and obtained marketing approval from the Ministry of Health, Labour and Welfare as a medical device in December 2018. Vascular distensibility testing using this product became eligible for public health insurance coverage in January 2019. The company is currently preparing for mass production and sales.」

「We are also advancing research and development into photoacoustic imaging for analysing microvascular information. The business was acquired from プレキシオン株式会社, a subsidiary of 株式会社船井興産, in July 2018.」

「In June 2018, we submitted an application to the PMDA (Pharmaceuticals and Medical Devices Agency) for marketing approval as a medical device for a compact, palm-sized vital sensor intended to detect arteriosclerosis and arrhythmia, the primary causes of cardiovascular diseases such as stroke and myocardial infarction, at an early stage.」

「We have completed consultations with the PMDA (Pharmaceuticals and Medical Devices Agency) regarding the palm-sized vital sensor, which measures arteriosclerosis and records electrocardiograms, and preparations for applying for medical device approval have entered the final stage.」

「We will strengthen and accelerate our business for preventing lifestyle diseases such as stroke and myocardial infarction by further increasing the functionality of the vital sensors we are developing and measuring and managing vascular information.」